The only test proven to predict likelihood of chemotherapy benefit1,2
- Provides a Recurrence Score ® result, which assesses the expression of 21 genes—16
cancer-related genes and 5 reference genes—in a tumor sample using reverse
transcription polymerase chain reaction (RT-PCR)3 - Comprehensive genomic assessment also includes risk of distant recurrence with endocrine therapy alone 4
- Predicts the benefit of adding chemotherapy to endocrine therapy1,2
- Provides a quantitative estrogen receptor (ER) score to help assess the magnitude of hormonal therapy benefit, along with additional supporting information such as progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) scores3
Gain insight into specific tumor biology, risk assessment, and magnitude of chemotherapy benefit to help inform what’s best for your patient.
Personalized insights for personalized treatment
Just as every patient is different, so is every tumor. The Breast Recurrence Score test uses genomics to give you and your doctor important risk information about how your individual tumor will likely behave. Valuable insights include:
- How likely you are to benefit from chemotherapy
- How likely your tumor is to spread
- The risk of your cancer recurring 1
- How likely your tumor is to benefit from hormone therapy alone
Is the Breast Recurrence Score test right for you?
You may be a candidate for the Breast Recurrence Score test if:
- You’ve been recently diagnosed with invasive breast cancer
- Your cancer is stage I, II, or IIIA
- Your breast cancer is hormone receptor-positive (HR+) and HER2-negative (HER2-)
